Concerns that elevated and non-pulsatile GH exposure may downregulate or desensitize GH receptor signaling were unfounded when a study by Laursen et al. (24) demonstrated that subjects who received continuous subcutaneous infusions of GH over 6 months maintained their serum IGF-I levels within the normal range and did not develop any signs or symptoms of acromegaly. The gene discussed is GH1; the disease is acromegaly.